Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD1 | P21728 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | DRD5 | P21918 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616336 | 0.98 | DRD2 (0.40) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16055031 | 0.84 | CA12 (0.46) | ALOX15NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16624215 | 0.79 | ALOX15 (0.44) | ALOX15NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16624220 | 0.77 | MAPT (0.37) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL16056780 | 0.76 | MRGPRX4 (0.47) | ALOX15NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL16624217 | 0.76 | ALOX15 (0.41) | ALOX15NPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL17535969 | 0.75 | GLA (0.47) | SMN1; SMN2MAPTTSHRLMNAGAA | |
| SCHEMBL3552508 | 0.75 | NPC1 (0.39) | ALOX15NPC1RAB9ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL16056187 | 0.75 | PLAT (0.44) | MAPTLMNACA12CA1CA2 | |
| SCHEMBL16056333 | 0.75 | FDFT1 (0.38) | MAPTLMNAGAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | DRD2 1287/4885DRD1 1948/4885DRD4 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.